Radyasyon pnömonisinin öngörülmesinde doz volüm histogramları ve TGF-β'nın yeri: Pilot çalışma
AMAÇ Torasik radyoterapi uygulanan küçük hücreli olmayan akciğer kanserli (KHOAK) hastalarda, radyasyon pnömonisi riski ile doz volüm histogramları (DVH) parametreleri ve plazma T G F -βseviyelerinin korelasyonu araştırıldı. GEREÇ VE YÖNTEM Bu çalışmaya üç boyutlu konformal radyoterapi uygulanan 15 KHOAK hastası dahil edildi. Radyoterapi dozu 50-66 Gy arası nda değişmekte olup, medyan doz 60 Gy idi. Olguların tümünde ipsilateral ve kontrlateral akciğerler için DVH’larından elde edilen MLD, V20, V30 değerleri incelendi. TGF-β seviyeleri ELISA yöntemi ile değerlendirildi.BULGULAR Olguların medyan takip süresi 16 ay idi (aralık 6-55). Bu süre içerisinde radyasyon pnömonisi üç olguda saptandı (1.,6. ve 9. aylarda). İpsilateral ve kontrlateral akciğerlerin doz par am e tr el eri karşılaştırıldığında, kontrlateral akciğ erlerin MLD, V20 ve V30 değerlerinin yüksek oluşu pnömoni gelişimi açısından anlamlı bulundu (p
The role of dose volume histograms and TGF-β in the prediction of radiation pneumonitis: a pilot study
OBJECTIVES To evaluate the role of some parameters of dose volume histograms (DVH) and plasma TGF-β levels in predicting radiation pneumonitis in non-small cell lung cancer (NSCLC) patients. METHODS Fifteen NSCLC patients treated with 3D conformal radiotherapy were included in the study. Radiotherapy dose was a median 60 Gy. Mean lung dose (MLD), V20 and V30 were calculated from both ipsilateral and contralateral lung DVH. TGF-β levels were studied with ELISA.RESULTS Median follow-up was 16 months (range 10-55). Radiation pneumonitis was diagnosed in three patients (6, 9, 12 months). Dose parameters of ipsi- and contralateral lungs revealed that higher MLD, V20, V30 values in contralateral lung were statistically significant for pneumonitis (p
___
- 1) Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47(1):5-27.
- 2) Murphy TP, Casey MT. Determination of operability in candidates who undergo lung resection for bronchogenic carcinoma. Can J Surg 1990;33(6):470-3.
- 3) Perez C, Azarnia N, Cox J. Sequela of definitive irradiation in the treatment of carcinoma of the lung. In: Motta G, editor. Lung cancer: advanced concepts and present status. Genoa, Italy: G Motta Publishing; 1989.
- 4) Emami B, Graham MV. Lung. In: Perez CA, Brady LW, editors. Principles and practice of radiation oncology. Philadelphia, New York: Lippincott-Raven; 1998. p. 1181-220.
- 5) Armstrong JG, Burman C, Leibel S, Fontenla D, Kutcher G, Zelefsky M, et al. Three-dimensional conformal radiation therapy may improve the therapeutic ratio of high dose radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 1993;26(4):685-9.
- 6) Martel MK, Ten Haken RK, Hazuka MB, Turrisi AT, Fraass BA, Lichter AS. Dose volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int J Radiat Oncol Biol Phys 1994;28(3):575-81.
- 7) Langer M, Kijewski P. CCRT (computer controlled radiation therapy) for non small cell lung cancer: sensitivity of clinical gains to organ tolerance restrictions. Int J Radiat Oncol Biol Phys 1992;22(2):325-32.
- 8) Marks LB, Munley MT, Bentel GC, Zhou SM, Hollis D, Scarfone C, et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys 1997;39(3):563-70.
- 9) Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 1995;33(1):99-109.
- 10) Franklin TJ. Therapeutic approaches to organ fibrosis. Int J Biochem Cell Biol 1997;29(1):79-89.
- 11) Grande JP. Role of transforming growth factor-beta in tissue injury and repair. Proc Soc Exp Biol Med 1997;214(1):27-40.
- 12) Anscher MS, Kong FM, Jirtle RL. The relevance of transforming growth factor beta 1 in pulmonary injury after radiation therapy. Lung Cancer 1998;19(2):109-20.
- 13) Rodemann HP, Bamberg M. Cellular basis of radiationinduced fibrosis. Radiother Oncol 1995;35(2):83-90.
- 14) Hakenjos L, Bamberg M, Rodemann HP. TGF-beta1-mediated alterations of rat lung fibroblast differentiation resulting in the radiation-induced fibrotic phenotype. Int J Radiat Biol 2000;76(4):503-9.
- 15) Martin M, Lefaix J, Delanian S. TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys 2000;47(2):277-90.
- 16) Travis EL. Organizational response of normal tissues to irradiation. Semin Radiat Oncol 2001;11(3):184-96.
- 17) Anscher MS, Murase T, Prescott DM, Marks LB, Reisenbichler H, Bentel GC, et al. Changes in plasma TGF beta levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. Int J Radiat Oncol Biol Phys 1994;30(3):671-6.
- 18) Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31(5):1341-6.
- 19) Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for nonsmall cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45(2):323 9.
- 20) Byhardt RW, Martin L, Pajak TF, Shin KH, Emami B, Cox JD. The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)-analysis of a Radiation Therapy Oncology Group (RTOG) protocol. Int J Radiat Oncol Biol Phys 1993;27(3):537-44.
- 21) Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21(1):109-22.
- 22) Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys 1989;16(6):1623-30.
- 23) Kutcher GJ, Burman C, Brewster L, Goitein M, Mohan R. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys 1991;21(1):137 46.
- 24) Lyman JT, Wolbarst AB. Optimization of radiation therapy, IV: A dose volume histogram reduction algorithm. Int J Radiat Oncol Biol Phys 1989;17(2):433-6.
- 25) Oetzel D, Schraube P, Hensley F, Sroka-Pérez G, Menke M, Flentje M. Estimation of pneumonitis risk in three-dimensional treatment planning using dosevolume histogram analysis. Int J Radiat Oncol Biol Phys 1995;33(2):455-60.
- 26) Yorke ED, Jackson A, Rosenzweig KE, Merrick SA, Gabrys D, Venkatraman ES, et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2002;54 (2):329-39.
- 27) Armstrong JG, Zelefsky MJ, Leibel SA, Burman C, Han C, Harrison LB, et al. Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer. Ann Oncol 1995;6(7):693-7.
- 28) Hernando ML, Marks LB, Bentel GC, Zhou SM, Hollis D, Das SK, et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 2001;51(3):650-9.
- 29) Sunyach MP, Falchero L, Pommier P, Perol M, Arpin D, Vincent M, et al. Prospective evaluation of early lung toxicity following three-dimensional conformal radiation therapy in non-small-cell lung cancer: preliminary results. Int J Radiat Oncol Biol Phys 2000;48(2):459-63.
- 30) Rubin P, Finkelstein J, Shapiro D. Molecular biology mechanisms in the radiation induction of pulmonary injury syndromes: interrelationship between the alveolar macrophage and the septal fibroblast. Int J Radiat Oncol Biol Phys 1992;24(1):93-101.
- 31) Anscher MS, Kong FM, Andrews K, Clough R, Marks LB, Bentel G, et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1998;41(5):1029-35.
- 32) Fan M, Marks LB, Hollis D, Bentel GG, Anscher MS, Sibley G, et al. Can we predict radiation-induced changes in pulmonary function based on the sum of predicted regional dysfunction? J Clin Oncol 2001;19(2):543-50.
- 33) Anscher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, et al. Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys 2003;56(4):988-95.
- 34) De Jaeger K, Seppenwoolde Y, Kampinga HH, Boersma LJ, Belderbos JS, Lebesque JV. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;58(5):1378-87.